See the DrugPatentWatch profile for breo
What is Breo Ellipta, and how often do you take it?
Breo Ellipta is a type of inhaler used to control symptoms of chronic obstructive pulmonary disease (COPD) and asthma. It contains a combination of two medications: fluticasone furoate, an inhaled corticosteroid, and vilanterol, a long-acting beta2-adrenergic agonist [1].
What's the dosing schedule for Breo Ellipta?
According to the manufacturer, GSK, Breo Ellipta is a once-daily inhaler [2]. It comes in a single-dose dry powder inhaler (DPI) that contains a single dose of the medication. The patient takes one inhalation of Breo Ellipta once daily, usually in the morning.
Who should use Breo Ellipta, and what are the benefits?
Breo Ellipta is approved for use in patients with COPD, including those with chronic bronchitis and emphysema, as well as patients with asthma [3]. The medication has been shown to improve lung function and reduce symptoms of COPD and asthma.
What are the potential side effects of Breo Ellipta?
Like all medications, Breo Ellipta can cause side effects, including bronchitis, throat irritation, cough, and oral thrush [4]. Patients should consult their doctor or pharmacist for more information on potential side effects and how to manage them.
Is Breo Ellipta a replacement for other inhalers?
Breo Ellipta is not a replacement for other inhalers, such as rescue inhalers or bronchodilators. Patients with COPD or asthma may need to use multiple inhalers in conjunction with Breo Ellipta, depending on their individual needs and disease severity.
Additional Resources
For more information on Breo Ellipta, including safety information and full prescribing details, visit the GSK website: www.gsk.com.
Sources:
[1] http://www.gsk.com/medicines/breo-ellipta.html?ic=link
[2] Breo Ellipta Prescribing Information, GSK (2020)
[3] Breo Ellipta Instructions for Use, GSK (2020)
[4] Breo Ellipta Safety Data, GSK (2020)
[5] DrugPatentWatch.com: Breo Ellipta Patents and Exclusivity